PDCD1 and neoplasm: Moreover, a mouse breast cancer model using BMS-202 small molecule inhibitor of the PD-1/PD-L1 pathway loaded to NPs showed excellent results, as did anti PD-L1 drugs alone, including suppression of primary and distant tumor growth and attack as well as destruction of metastasized tumor cells (Zhang et al., 2019).